Literature DB >> 20687839

Not all patients with vancomycin-resistant enterococci need to be isolated.

S Tschudin Sutter1, R Frei, M Dangel, A Gratwohl, M Bonten, A F Widmer.   

Abstract

BACKGROUND: Vancomycin-resistant enterococci (VRE) have triggered multiple outbreaks. However, VRE of genotype vanC appear not to be associated with outbreaks. The goal of this study was to estimate the risk of bloodstream infections in patients colonized with VRE of genotype vanC who received care from a bone marrow transplant unit for patients with leukemia, where only standard precautions were implemented for VRE of genotype vanC during the last 9 years.
METHODS: Since 2000, all patients in the bone marrow transplant unit underwent routine VRE rectal screening, data were prospectively entered in a database, and isolates were molecularly characterized. Infection control policy required contact isolation for patients infected with VRE of genotype vanA or vanB but only standard precautions for patients infected with VRE of genotype vanC.
RESULTS: From January 2000 to July 2008, 290 isolates of VRE of genotype vanC obtained from 273 different patients were identified, with an incidence of 25-43 isolates/year. Of 290 isolates, 285 (98%) were identified in rectal screening swabs, 5 were from other body sites, and none required specific treatment. During the entire study period, only 1 case of bloodstream infection was detected, reflecting an incidence of 1 (0.4%) of the 273 patients, or <0.2 cases per 1000 patient-days. No outbreaks were recorded.
CONCLUSIONS: These data provide strong evidence that carriers of VRE of genotype vanC do not require contact isolation, thereby saving resources and potentially improving patient care. The genotype should be routinely determined in areas with a high prevalence of VRE of genotype vanC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20687839     DOI: 10.1086/655824

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  6 in total

1.  Pretransplant Gut Colonization with Intrinsically Vancomycin-Resistant Enterococci (E. gallinarum and E. casseliflavus) and Outcomes of Allogeneic Hematopoietic Cell Transplantation.

Authors:  Armin Rashidi; Maryam Ebadi; Robin R Shields-Cutler; Todd E DeFor; Gabriel A Al-Ghalith; Patricia Ferrieri; Jo-Anne H Young; Gary M Dunny; Dan Knights; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2018-01-31       Impact factor: 5.742

2.  Vancomycin-resistance gene cluster, vanC, in the gut microbiome of acute leukemia patients undergoing intensive chemotherapy.

Authors:  Armin Rashidi; Zhigang Zhu; Thomas Kaiser; Dawn A Manias; Shernan G Holtan; Tauseef Ur Rehman; Daniel J Weisdorf; Alexander Khoruts; Gary M Dunny; Christopher Staley
Journal:  PLoS One       Date:  2019-10-10       Impact factor: 3.240

3.  Vancomycin-Nonsusceptible Enterococci Mediated by vanC at a Large Children's Hospital: Prevalence, Susceptibility, and Impact on Care of Enterococcal Bacteremia.

Authors:  Daniel S Dodson; Samuel R Dominguez; Christine E MacBrayne; Manon C Williams; Sarah K Parker
Journal:  Open Forum Infect Dis       Date:  2020-05-06       Impact factor: 3.835

4.  Detection and molecular characterization of VRE isolates in Slovakia from stool samples positive for Clostridioides difficile toxins.

Authors:  Jozef Kuzma; Lenka Palcová; Jaroslav Timko; Veronika Bastová; Veronika Janošcová; Dittmar Chmelař
Journal:  Folia Microbiol (Praha)       Date:  2022-08-23       Impact factor: 2.629

5.  Trends and significance of VRE colonization in the ICU: a meta-analysis of published studies.

Authors:  Panayiotis D Ziakas; Rachana Thapa; Louis B Rice; Eleftherios Mylonakis
Journal:  PLoS One       Date:  2013-09-27       Impact factor: 3.240

6.  First Report of the Local Spread of Vancomycin-Resistant Enterococci Ascribed to the Interspecies Transmission of a vanA Gene Cluster-Carrying Linear Plasmid.

Authors:  Yusuke Hashimoto; Izumi Kita; Masato Suzuki; Hidetada Hirakawa; Hirofumi Ohtaki; Haruyoshi Tomita
Journal:  mSphere       Date:  2020-04-08       Impact factor: 4.389

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.